88IV - PR Newswire Asia's news


Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local ... 2026-04-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy Study published in SCIE-indexed international journal Molecular Neurobiology Three intravenous infusions at four-week intervals showed benefits in cognition, brain metabolism, and structural preservation ... 2026-04-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight ... 2026-04-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival CHENGDU, China , April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion ... 2026-04-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery ... 2026-04-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Servier completes the acquisition of Day One Biopharmaceuticals Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDA TM in the U.S . in pediatric low-grade glioma. Transaction also includes a strong oncology ... 2026-04-23T Banking/Financial Service Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Fosun Health Strengthens Regional Presence at GlobalHealth Asia-Pacific Forum 2026, Showcasing "China Solution" and Winning Three Major Awards JAKARTA, Indonesia , April 23, 2026 /PRNewswire/ -- Fosun Health made a prominent debut at the GlobalHealth Asia-Pacific Healthcare Insights & Leadership Forum 2026, held alongside the GlobalHealth ... 2026-04-23T Biotechnology Health Care/Hospital Medical/Pharmaceuticals Travel
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer SHANGHAI , April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical ... 2026-04-23T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
2026 ASCO \| Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations SHANGHAI , April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results ... 2026-04-23T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia Minjuvi ® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in ... 2026-04-23T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology